Combretastatin A-4 phosphate

Combretastatin A-4 phosphate (fosbretabulin, and its salt fosbretabulin disodium) is a microtubule destabilising drug, a type of vascular-targeting agent, a drug designed to damage the vasculature (blood vessels) of cancer tumours causing central necrosis. It is a derivative of combretastatin.

Combretastatin A-4 phosphate
Clinical data
Other namesCA4P; CA4PD; fosbretabulin; fosbretabulin disodium
Identifiers
PubChem CID
ChemSpider
Chemical and physical data
FormulaC18H21O8P
Molar mass396.332 g·mol−1
3D model (JSmol)
  (verify)
For more information about this drug and its actions, see combretastatin.

Combretastatin A-4 phosphate (CA4P) is a prodrug. In vivo, it is dephosphorylated to its active metabolite, combretastatin A-4.[1]

CA4P is also known as Fosbretabulin Tromethamine.[2]

In July 2007 the pharmaceutical company OXiGENE initiated a 180-patient phase III clinical trial of CA-4-P in combination with carboplatin for the treatment of anaplastic thyroid cancer.[3] There is currently no fully FDA approved treatment for this form of cancer.

By 2017 it had completed multiple clinical trials (e.g. for solid tumours,[4] non-small cell lung cancer[5]) with more in progress.[6]

See also

References
  1. Combretastatin A-4 phosphate on www.cancer.gov
  2. A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers (GI-NETorPNET)
  3. Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
  4. Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
  5. A Safety and Efficacy Study of Carboplatin, Paclitaxel, Bevacizumab and CA4P in Non-Small Cell Lung Cancer (FALCON)
  6. CA4P clinical trials


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.